117 reports of this reaction
2.2% of all CEVIMELINE HYDROCHLORIDE reports
#8 most reported adverse reaction
ARTHRALGIA is the #8 most commonly reported adverse reaction for CEVIMELINE HYDROCHLORIDE, manufactured by Aurobindo Pharma Limited. There are 117 FDA adverse event reports linking CEVIMELINE HYDROCHLORIDE to ARTHRALGIA. This represents approximately 2.2% of all 5,260 adverse event reports for this drug.
Patients taking CEVIMELINE HYDROCHLORIDE who experience arthralgia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ARTHRALGIA is a less commonly reported adverse event for CEVIMELINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to arthralgia, the following adverse reactions have been reported for CEVIMELINE HYDROCHLORIDE:
The following drugs have also been linked to arthralgia in FDA adverse event reports:
ARTHRALGIA has been reported as an adverse event in 117 FDA reports for CEVIMELINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ARTHRALGIA accounts for approximately 2.2% of all adverse event reports for CEVIMELINE HYDROCHLORIDE, making it a notable side effect.
If you experience arthralgia while taking CEVIMELINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.